Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scatter factor and angiogenesis

E M Rosen1, I D Goldberg

  • 1Department of Radiation Oncology, Long Island Jewish Medical Center, New Hyde Park, New York 11042, USA.

Advances in Cancer Research
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary oxidative stress biomarker levels and reproductive outcomes among couples undergoing fertility treatments.

Human reproduction (Oxford, England)·2019
Same author

Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

Oncogene·2007
Same author

Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.

Oncogene·2007
Same author

Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells.

Oncogene·2006
Same author

BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells.

British journal of cancer·2006
Same author

BRCA1 in hormonal carcinogenesis: basic and clinical research.

Endocrine-related cancer·2005
Same journal

Cancer immunotherapy with oncolytic myxoma virus.

Advances in cancer research·2026
Same journal

Cancer terminator viruses: Unique conditionally replication competent oncolytic viruses producing therapeutic anti-cancer immunomodulating agents.

Advances in cancer research·2026
Same journal

Advancing clinical translation of oncolytic adenoviruses.

Advances in cancer research·2026
Same journal

Operation oncolysis: Reoviruses in the theater of cancer war.

Advances in cancer research·2026
Same journal

AAV vectors for cancer gene therapy.

Advances in cancer research·2026
Same journal

Vesicular stomatitis virus (VSV) as an oncolytic therapeutic agent for cancer.

Advances in cancer research·2026
See all related articles

Scatter factor (SF) promotes tumor growth and blood vessel formation by stimulating cell motility and proliferation via the c-met receptor. Inhibiting this pathway may offer new cancer therapies.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Medicine

Background:

  • Scatter factor (SF), also known as hepatocyte growth factor, is a cytokine that regulates epithelial cell behavior.
  • SF signals through the c-met receptor, a tyrosine kinase, influencing cell motility, proliferation, and morphogenesis.
  • SF is a potent angiogenic factor, promoting blood vessel formation, and is often overexpressed in tumors.

Purpose of the Study:

  • To investigate the role of the SF/c-met pathway in tumor angiogenesis and invasion.
  • To explore the hypothesis that tumor suppressor gene mutations activate the SF/c-met pathway, promoting an invasive and angiogenic tumor phenotype.

Main Methods:

  • Review of existing literature on Scatter Factor, c-met signaling, and tumor angiogenesis.
  • Analysis of the proposed SF-IF-->SF-->c-met pathway in tumor development.

Related Experiment Videos

Main Results:

  • SF directly stimulates endothelial cell functions crucial for angiogenesis, including motility, proliferation, invasion, and tube formation.
  • Tumor cells may induce SF production in stromal cells via secreted factors (SF-IFs), contributing to tumor angiogenesis.
  • Tumor suppressor gene mutations are hypothesized to activate this pathway, leading to invasive and angiogenic tumors.

Conclusions:

  • The SF/c-met pathway plays a significant role in tumor angiogenesis and invasion.
  • Dysregulation of tumor suppressor genes may activate this pathway, driving malignant phenotypes.
  • Targeting the SF/c-met pathway presents a potential therapeutic strategy for modulating tumor angiogenesis.